5,6,11,12-tetrahydrobenzo<5,6>cycloheptaindol-6-one | 35150-51-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5,6,11,12-tetrahydrobenzo<5,6>cycloheptaindol-6-one
• 英文别名: 5,6,11,12-tetrahydrobenzo[5,6]cyclohepta[b]indol-6-one；11,12-Dihydrobenzo[5,6]cyclohepta[1,2-b]indol-6(5H)-one；18-Azatetracyclo[9.7.0.03,8.012,17]octadeca-1(11),3,5,7,12,14,16-heptaen-2-one
• CAS: 35150-51-7
• 化学式: C₁₇H₁₃NO
• 分子量: 247.296
• InChiKey: JSJHCLSBJPUCBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5,6,11,12-tetrahydrobenzo<5,6>cycloheptaindol-6-one 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 1,4-二氧六环 为溶剂， 反应 12.0h， 以85%的产率得到5,6-dihydrobenzo<5,6>cycloheptaindol-6-one
  参考文献：
  名称：

  Synthesis of benzo[5,6]cyclohepta[b]indol-6-one derivatives

  摘要：

  An effective synthesis 5,6,11,12-tetrahydrobenzo[5,6]cyclohepta[b]indole-6-ones 2 was reported. Reactivity studies of the compound 2a led us to the preparation of 11-substituted derivatives 9-13 via the palladium-mediated cross-coupling reactions or an elimination-addition reaction. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00122-2
• 作为产物：
  描述：

  2-<2-(Indole-3-yl)ethyl>benzoic acid 在 磷酸酐 、 PPA 作用下， 反应 1.0h， 以80%的产率得到5,6,11,12-tetrahydrobenzo<5,6>cycloheptaindol-6-one
  参考文献：
  名称：

  Synthesis of benzo[5,6]cyclohepta[b]indol-6-one derivatives

  摘要：

  An effective synthesis 5,6,11,12-tetrahydrobenzo[5,6]cyclohepta[b]indole-6-ones 2 was reported. Reactivity studies of the compound 2a led us to the preparation of 11-substituted derivatives 9-13 via the palladium-mediated cross-coupling reactions or an elimination-addition reaction. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00122-2

文献信息

• Synthesis and in Vitro Cytotoxic Evaluation of N-Substituted Benzo[5,6]cyclohepta[b]indoles.
  作者：Benoit JOSEPH、David ALAGILLE、Jean-Yves MEROUR、Stephane LEONCE

  DOI：10.1248/cpb.48.1872

  日期：——

  A new series of N-substituted benzo[5, 6]cyclohepta[b]indole derivatives were synthesised and evaluated for in vitro cytotoxic activities against L1210 murine leukemia and HT29 cell lines. Among them, several compounds showed potent antitumor activity and blocked cell cycle progression of L1210 cells in G2+M phase.

  合成了一系列新的 N-取代苯并[5, 6]环庚烷并[b]吲哚衍生物，并评估了它们对 L1210 小鼠白血病和 HT29 细胞株的体外细胞毒性活性。在这些化合物中，有几种化合物显示出了强大的抗肿瘤活性，并阻断了 L1210 细胞在 G2+M 期的细胞周期进程。
• Fused polycyclic compounds, compositions, methods of manufacture, and their use as PAF antagonists, antihistamines and/or antiinflammatory agents
  申请人：SCHERING CORPORATION

  公开号：EP0339978B1

  公开（公告）日：1996-08-21
• FUSED POLYCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE AND THEIR USE AS PAF ANTAGONISTS, ANTIHISTAMINES AND/OR ANTIINFLAMMATORY AGENTS
  申请人：SCHERING CORPORATION

  公开号：EP0412988A1

  公开（公告）日：1991-02-20
• [EN] FUSED POLYCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE AND THEIR USE AS PAF ANTAGONISTS, ANTIHISTAMINES AND/OR ANTIINFLAMMATORY AGENTS
  申请人：SCHERING CORPORATION

  公开号：WO1989010363A1

  公开（公告）日：1989-11-02

  (EN) Fused polycyclic heterocyclic compounds of generalized formula (I), their use as PAF-antagonists, antihistamines and/or antiinflammatory agents, methods of manufacture and pharmaceutical compositions incorporating said compounds are disclosed.(FR) L'invention concerne des composés hétérocycliques polycycliques fusionnés de la formule (I), leur utilisation comme antogonistes du PAF (facteur d'agrégation de plaquettes), des antihistamines et/ou des agents anti-inflammatoires, des procédés de fabrication ainsi que des compositions pharmaceutiques comprenant lesdits composés.
• Synthesis of benzo[5,6]cyclohepta[b]indol-6-one derivatives
  作者：Benoît Joseph、David Alagille、Cyril Rousseau、Jean-Yves Mérour

  DOI：10.1016/s0040-4020(99)00122-2

  日期：1999.4

  An effective synthesis 5,6,11,12-tetrahydrobenzo[5,6]cyclohepta[b]indole-6-ones 2 was reported. Reactivity studies of the compound 2a led us to the preparation of 11-substituted derivatives 9-13 via the palladium-mediated cross-coupling reactions or an elimination-addition reaction. (C) 1999 Elsevier Science Ltd. All rights reserved.